Kymera Investor Presentation Deck

● ● ● KT-474 Phase 1 Trial Design and Summary Healthy Volunteers (HV), SAD and MAD 9 SAD cohorts 8 subjects per cohort (6:2 randomization) including 2 food-effect cohorts 72 adult healthy subjects dosed Single dose (25-1600 mg) 5 MAD cohorts 12 subjects per cohort (9:3 randomization) 60 adult healthy subjects dosed 14x daily doses (25-200 mg, MAD 1-4); 5x twice-weekly doses (200 mg, MAD5) Summary of Key Findings in Healthy Volunteers IRAK4 reduction to near lower limit of quantification with Mass Spectrometry Degradation associated with up to 85% inhibition of multiple disease-relevant cytokines and chemokines in ex vivo TLR stimulation assay at 100 mg dose Dose-dependent IRAK4 degradation in skin of >50% Generally well tolerated at doses up to 200 mg with no SAEs KYMERA ©2023 KYMERA THERAPEUTICS, INC. ● ● HS and AD Patients 1 cohort 21 HS and AD patients 75 mg (fed state) (~equivalent exposure to 100mg fasted MAD cohort dose level) Open-label 28x daily doses Summary of Key Findings in Patients Safety, PK and PD comparable to healthy volunteers Robust degradation of IRAK4 in blood and skin was associated with systemic anti-inflammatory effect in HS and AD patients Promising clinical activity observed in HS and AD exceeding benchmark placebo rates and comparing favorably to SOC biologics Results support advancing KT-474 into Phase 2 placebo-controlled trials; Sanofi has committed to start Ph2 clinical trials, initially in HS and AD PAGE 12

View entire presentation